Shiloh
Editor, Senior Moderator
Source: https://www.dailymail.co.uk/health/...ial-significantly-improves-lung-function.html
Hope for cystic fibrosis patients as 'impressive' three-drug trial 'significantly' improves lung function and more than halves flare-ups for people with the most common type
Trikafta is combo of three drugs which targets gene responsible for the disorder
FDA approved it after major trial showed it slashed symptoms by 63 per cent
Findings hailed as 'cause for celebration' for patients with chronic, fatal illness
By Connor Boyd Health Reporter For Mailonline
Published: 12:30 EDT, 1 November 2019 | Updated: 12:32 EDT, 1 November 2019
Thousands of cystic fibrosis patients could have a ray of hope after a three-drug therapy was shown to improve lung function and dramatically reduce symptoms.
The treatment, called trikafta, targets a gene responsible for the life-threatening disorder in around 90 per cent of patients.
The US Food and Drug Administration (FDA) approved the drug combination earlier this month based on the results of a landmark international study.
Led by the University of Texas, it found lung function was 'significantly' improved within a month and flare-ups were 63 per cent less common...
Hope for cystic fibrosis patients as 'impressive' three-drug trial 'significantly' improves lung function and more than halves flare-ups for people with the most common type
Trikafta is combo of three drugs which targets gene responsible for the disorder
FDA approved it after major trial showed it slashed symptoms by 63 per cent
Findings hailed as 'cause for celebration' for patients with chronic, fatal illness
By Connor Boyd Health Reporter For Mailonline
Published: 12:30 EDT, 1 November 2019 | Updated: 12:32 EDT, 1 November 2019
Thousands of cystic fibrosis patients could have a ray of hope after a three-drug therapy was shown to improve lung function and dramatically reduce symptoms.
The treatment, called trikafta, targets a gene responsible for the life-threatening disorder in around 90 per cent of patients.
The US Food and Drug Administration (FDA) approved the drug combination earlier this month based on the results of a landmark international study.
Led by the University of Texas, it found lung function was 'significantly' improved within a month and flare-ups were 63 per cent less common...